MRTX stock crashes after mid-stage data for KRAS inhibitor in lung cancer (NASDAQ:MRTX)
wildpixel/iStock through Getty Photographs Mirati Therapeutics (NASDAQ:MRTX) plunged 23% within the post-market Thursday after the clinical-stage oncology firm shared trial ...